After vitrectomy for DME, visual acuity and CFT improved significantly in both groups, but only patients treated with kallidinogenase continued to have significant improvement throughout the study period.

In the study group, the visual acuity and CFT significantly improved from 3 to 12Â months and from 6 to 12Â months, whereas these parameters did not continue to improve in the control group after 6 months (for visual acuity) or 3 months (for CFT). At 12Â months, the mean CFT decreased significantly in both groups, with no significant difference in the rate of change between the two groups. The degree of improvement did not differ significantly between the groups. Visual acuity improved significantly at 12Â months in both groups compared with before surgery. During follow-up, 11 patients dropped out (six in the study group and five in the control group), leaving 28 eyes in 28 patients for analysis (13 in the study group and 15 in the control group). The main outcome measurements included logMAR visual acuity and central foveal thickness (CFT) before surgery and at 3, 6, 9, and 12Â months after vitrectomy. This study was designed as a prospective, randomized, multicenter study comparing 19 eyes of 19 patients who received 150 units of kallidinogenase administered a day for 52Â weeks from the day after vitrectomy (study group) with 20 eyes of 20 patients who received no kallidinogenase (control group).

To evaluate the effectiveness of the combination of vitrectomy with kallidinogenase for diabetic macular edema (DME). Yoshizumi, Yuki Ohara, Zaigen Tabuchi, Hitoshi Sumino, Hitomi Maeda, Yukiko Mochizuki, Hideki Yamane, Ken Kiuchi, Yoshiaki Effects of kallidinogenase in patients undergoing vitrectomy for diabetic macular edema.

Instal Miranda NG 0.96.3